Citation Impact
Citing Papers
Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes
2015 Standout
Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps
2019
Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
2007 StandoutScience
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
Cancer statistics, 2017
2017 Standout
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2018 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology
2019
Confounding factors of non-invasive tests for nonalcoholic fatty liver disease
2020
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
2018
Nonalcoholic fatty liver associated with impairment of kidney function in nondiabetes population.
2012
Limitations of non-invasive tests for assessment of liver fibrosis
2020
Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease
2016
Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD
2015
Body Fatness and Cancer — Viewpoint of the IARC Working Group
2016 Standout
Hepatocellular carcinoma
2018 Standout
Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease
2010
Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
2020
Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis
2014
In vitro cytotoxicity assays: Comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride
2005 Standout
Molecular viral oncology of hepatocellular carcinoma
2003
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
2017 Standout
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
2005 Standout
Liver Injury and Disease Pathogenesis in Chronic Hepatitis C
2013
Excess body weight and the risk of primary liver cancer: An updated meta-analysis of prospective studies
2012
Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol
2016
Steatosis and insulin resistance in response to treatment of chronic hepatitis C
2012
Population-Attributable Fractions of Risk Factors for Hepatocellular Carcinoma in the United States
2013
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis
2020
Ethylbenzene Induces Microsomal Oxygen Free Radical Generation: Antibody-Directed Characterization of the Responsible Cytochrome P450 Enzymes
2000
Hepatocellular carcinoma
2012 Standout
Cancer and viral infections in immunocompromised individuals
2009
Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress
2004
Pathological Features of Fatty Liver Disease
2014
Psoriasis
2021 Standout
Use of Liver Imaging and Biopsy in Clinical Practice
2017
Update on Nonalcoholic Fatty Liver Disease
2002
Regulation of glutathione synthesis
2008 Standout
NAFLD and diabetes mellitus
2016
Hepatotoxicity and Mechanism of Action of Haloalkanes: Carbon Tetrachloride as a Toxicological Model
2003 Standout
Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis
2015
Nonalcoholic Steatohepatitis is the Most Rapidly Growing Indication for Simultaneous Liver Kidney Transplantation in the United States
2015
Mitochondrial dysfunction in cholestatic liver diseases
2011
Cytokeratin-18 Fragment Levels as Noninvasive Biomarkers for Nonalcoholic Steatohepatitis
2009
Genetic predisposition in nonalcoholic fatty liver disease
2017
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: Is there a link?
2010
Noninvasive biomarkers in NAFLD and NASH — current progress and future promise
2018
Viral hepatitis and liver cancer: the case of hepatitis C
2006
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors
2014
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
2020
A role of PIEZO1 in iron metabolism in mice and humans
2021 StandoutNobel
Non-alcoholic fatty liver disease
2021 Standout
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association
2021 Standout
SGLT2 Inhibitors in Liver Patients
2020
The genetics of NAFLD
2013
Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver Disease
2015
Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date
2019
Serum Ferritin Is An Independent Predictor of Histologic Severity and Advanced Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
2011
Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity
2010
Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016
2016
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
2013
CKD and Nonalcoholic Fatty Liver Disease
2014
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
2014 Standout
Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease
2016
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
2012
Toward Genetic Prediction of Nonalcoholic Fatty Liver Disease Trajectories: PNPLA3 and Beyond
2020
Mechanisms of fatty acid-induced inhibition of glucose uptake.
1994 Standout
Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease
2011
NAFLD in Asia—as common and important as in the West
2013
Advances in functional and molecular MRI technologies in chronic liver diseases
2020
IgG4-related disease
2014 Standout
Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease
2016
A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis
2004
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
2012 Standout
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
2014
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
2015 Standout
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Extrahepatic complications of nonalcoholic fatty liver disease
2013
Non-alcoholic fatty liver disease and the interface between primary and secondary care
2018
Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up
2012
NF-κB functions as a tumour promoter in inflammation-associated cancer
2004 StandoutNature
Diversity, stability and resilience of the human gut microbiota
2012 StandoutNature
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
2010 Standout
Hepatocellular Carcinoma
2011 Standout
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
Increased risk of cardiovascular disease and chronic kidney disease in NAFLD
2012
Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus–Related Cirrhosis
2009
Mechanisms of non-alcoholic steatohepatitis
2004
NAFLD: A multisystem disease
2015 Standout
Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go?
2014
Pre-eclampsia
2015 Standout
Hepatocellular carcinoma
2022 Standout
Early life exposures
2011
Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis
2017
Hepatitis C Virus RNA Functionally Sequesters miR-122
2015 StandoutNobel
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Mitochondrial dysfunction in cholestatic liver diseases
2012
The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2
2015
Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis
2015
Hepatocellular Carcinoma
2019 Standout
CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
2019
Surveillance for Hepatocellular Carcinoma in Patients with NASH
2016
Tirzepatide Once Weekly for the Treatment of Obesity
2022 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
A diabetologist’s perspective of non‐alcoholic steatohepatitis (NASH): Knowledge gaps and future directions
2020
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study
2015
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions
2017
Redefining Preeclampsia Using Placenta-Derived Biomarkers
2013
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity
2016
Once-Weekly Semaglutide in Adults with Overweight or Obesity
2021 Standout
Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome
2018
Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
2016
Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 1: Definition, risk factors and assessment
2017
Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study
2019
The Promise of Angiogenic Markers for the Early Diagnosis and Prediction of Preeclampsia
2012
NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management
2019
Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers
2019
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
The Role of Iron and Iron Overload in Chronic Liver Disease
2016
Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
2022
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science
2017
Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
2017 Standout
Nonalcoholic Fatty Liver Disease
2015 Standout
Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease
2011
Review article: omega‐3 fatty acids – a promising novel therapy for non‐alcoholic fatty liver disease
2009
Fast detection of liver fibrosis with collagen-binding single-nanometer iron oxide nanoparticles via T 1 -weighted MRI
2023 StandoutNobel
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Structure and Chemistry of Cytochrome P450
2005 Standout
Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease
2019
Works of Yoshio Sumida being referenced
Evidence of oxidative stress as a cofactor in the development of insulin resistance in patients with chronic hepatitis C
2007
Inverse association between Helicobacter pylori infection and allergic rhinitis in young Japanese
2010
Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population
2012
Role of hepatic iron in non‐alcoholic steatohepatitis
2008
Different profiles of circulating angiogenic factors and adipocytokines between early‐ and late‐onset pre‐eclampsia
2010
Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease
2002
Ursodeoxycholic Acid Protects Hepatocytes against Oxidative Injury via Induction of Antioxidants
1999
Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011–2012
2014
The association of insomnia with gastroesophageal reflux symptoms in biopsy-proven nonalcoholic fatty liver disease
2013
Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials
2017
Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
2018
Lower circulating levels of dehydroepiandrosterone, independent of insulin resistance, is an important determinant of severity of non‐alcoholic steatohepatitis in Japanese patients
2010
Current and future pharmacological therapies for NAFLD/NASH
2017
Natural Course of Asymptomatic Hepatitis C Virus–Infected Patients and Hepatocellular Carcinoma After Interferon Therapy
2005
Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients
2013
Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection
2000
Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography
2015
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
2015
LDL-Migration Index (LDL-MI), an Indicator of Small Dense Low-Density Lipoprotein (sdLDL), Is Higher in Non-Alcoholic Steatohepatitis than in Non-Alcoholic Fatty Liver: A Multicenter Cross-Sectional Study
2014
Nonalcoholic steatohepatitis and increased risk of chronic kidney disease
2010
A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease
2010
Effects of Glycyrrhizin on Glucocorticoid Signaling Pathway in Hepatocytes
2002
Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
2014
Genetic Polymorphisms of the Human PNPLA3 Gene Are Strongly Associated with Severity of Non-Alcoholic Fatty Liver Disease in Japanese
2012
Characteristics of Patients With Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma
2011
The Impact of PNPLA3 rs738409 Genetic Polymorphism and Weight Gain ≥10 kg after Age 20 on Non-Alcoholic Fatty Liver Disease in Non-Obese Japanese Individuals
2015
Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non‐alcoholic fatty liver disease and type 2 diabetes mellitus
2016
Serum Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein levels and liver fibrosis: A meta‐analysis
2017
Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection
2000
Lower levels of insulin‐like growth factor‐1 standard deviation score are associated with histological severity of non‐alcoholic fatty liver disease
2014
Pathological findings of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
2016
[A case of autoimmune pancreatitis occurring during intravesical bacillus Calmette Guerin immunotherapy for ureteral cancer].
2003
Effect of 12‐week dulaglutide therapy in Japanese patients with biopsy‐proven non‐alcoholic fatty liver disease and type 2 diabetes mellitus
2016
Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
2015
A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers
2015
Predictors of malignancies and overall mortality in J apanese patients with biopsy‐proven non‐alcoholic fatty liver disease
2014